DiMasi JA - Search Results

1

Assessing the net financial benefits of employing digital endpoints in clinical trials.

DiMasi JA, Dirks A, Smith Z, Valentine S, Goldsack JC, Metcalfe T, Grewal U, Leyens L, Conradi U, Karlin D, Maloney L, Getz KA, Hartog B. DiMasi JA, et al. Clin Transl Sci. 2024 Aug;17(8):e13902. doi: 10.1111/cts.13902. Clin Transl Sci. 2024. PMID: 39072949 Free PMC article.

2

Drug development costs when financial risk is measured using the Fama-French three-factor model.

Vernon JA, Golec JH, Dimasi JA. Vernon JA, et al. Among authors: dimasi ja. Health Econ. 2010 Aug;19(8):1002-5. doi: 10.1002/hec.1538. Health Econ. 2010. PMID: 19655335

3

The roles of patents and research and development incentives in biopharmaceutical innovation.

Grabowski HG, DiMasi JA, Long G. Grabowski HG, et al. Among authors: dimasi ja. Health Aff (Millwood). 2015 Feb;34(2):302-10. doi: 10.1377/hlthaff.2014.1047. Health Aff (Millwood). 2015. PMID: 25646111

4

A Tool for Predicting Regulatory Approval After Phase II Testing of New Oncology Compounds.

DiMasi JA, Hermann JC, Twyman K, Kondru RK, Stergiopoulos S, Getz KA, Rackoff W. DiMasi JA, et al. Clin Pharmacol Ther. 2015 Nov;98(5):506-13. doi: 10.1002/cpt.194. Epub 2015 Sep 24. Clin Pharmacol Ther. 2015. PMID: 26239772

5

Cost Drivers of a Hospital-Acquired Bacterial Pneumonia and Ventilator-Associated Bacterial Pneumonia Phase 3 Clinical Trial.

Stergiopoulos S, Calvert SB, Brown CA, Awatin J, Tenaerts P, Holland TL, DiMasi JA, Getz KA. Stergiopoulos S, et al. Among authors: dimasi ja. Clin Infect Dis. 2018 Jan 6;66(1):72-80. doi: 10.1093/cid/cix726. Clin Infect Dis. 2018. PMID: 29020279 Free PMC article. Clinical Trial.

6

Assessing the Financial Value of Patient Engagement: A Quantitative Approach from CTTI's Patient Groups and Clinical Trials Project.

Levitan B, Getz K, Eisenstein EL, Goldberg M, Harker M, Hesterlee S, Patrick-Lake B, Roberts JN, DiMasi J. Levitan B, et al. Ther Innov Regul Sci. 2018 Mar;52(2):220-229. doi: 10.1177/2168479017716715. Epub 2017 Jul 17. Ther Innov Regul Sci. 2018. PMID: 29714515 Free PMC article.

7

Assessing the Financial Benefits of Faster Development Times: The Case of Single-source Versus Multi-vendor Outsourced Biopharmaceutical Manufacturing.

DiMasi JA, Smith Z, Getz KA. DiMasi JA, et al. Clin Ther. 2018 Jun;40(6):963-972. doi: 10.1016/j.clinthera.2018.04.011. Epub 2018 May 11. Clin Ther. 2018. PMID: 29755005

8

Analysis of Review Times for Recent 505(b)(2) Applications.

Sakai S, DiMasi JA, Getz KA. Sakai S, et al. Among authors: dimasi ja. Ther Innov Regul Sci. 2017 Sep;51(5):651-656. doi: 10.1177/2168479017703138. Epub 2017 Apr 16. Ther Innov Regul Sci. 2017. PMID: 30231691

9

The Impact of Collaborative and Risk-Sharing Innovation Approaches on Clinical and Regulatory Cycle Times.

DiMasi JA, Kim J, Getz KA. DiMasi JA, et al. Ther Innov Regul Sci. 2014 Jul;48(4):482-487. doi: 10.1177/2168479014521419. Ther Innov Regul Sci. 2014. PMID: 30235569

10

Development Times and Approval Success Rates for Drugs to Treat Infectious Diseases.

DiMasi JA, Florez MI, Stergiopoulos S, Peña Y, Smith Z, Wilkinson M, Getz KA. DiMasi JA, et al. Clin Pharmacol Ther. 2020 Feb;107(2):324-332. doi: 10.1002/cpt.1627. Epub 2019 Oct 11. Clin Pharmacol Ther. 2020. PMID: 31502248

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

56 results

Search Page

Filters